CClinicalTrials.gg
Not yet recruitingNCT07459010Updated Mar 9, 2026

ACT Dad's Power: Feasibility RCT for Fathers of Children With Special Needs

An interventional study of VR-based ACT and Health Talks and Simple Social Support in Developmental Disabilities, sponsored by The Hong Kong Polytechnic University. Not yet recruiting. Open to male participants. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Sex
Male
01

Study summary

Objective: (1) To examine the feasibility of proceeding to a future definitive RCT of ACT in Hong Kong Chinese fathers rearing children with special needs. (2) To calculate the effect sizes of the intervention on fathers' psychological flexibility, shame, guilt, and quality of life (QoL) at the 6-month follow-up. (3) To calculate the potential efficacy of the intervention.

Methods: A 2-arm feasibility randomised controlled trail will be conducted on 50 fathers of children with special needs. 25 participants will be allocated into the intervention group to attend 6 weekly 45-60 minute sessions of ACT with VR. 25 participants will be allocated to the control group receiving 6 weekly 45-60 minute sessions of health talks and simple social support.

Outcome and measurement: Primary outcomes are screening rate, eligibility rate, consent rate, randomization rate, attendance rate, adherence rate, retention rate, completion rate, missing data, and adverse events. Secondary outcomes are the effect sizes and preliminary efficacy of the intervention on psychological flexibility, shame, guilt, depressive symptoms, and QoL at T4. Both groups will be required to fill in a set of questionnaires at the start of intervention (T1), post-intervention (T2), 3 (T3), and 6 months (T4) after the end of intervention. They will also be invited to join semi-structure interviews at T2.

Data analysis: Descriptive statistics, mixed between-within-participants analysis of variance, and content analysis will be used.

02

Conditions studied

  • Developmental Disabilities

Keywords

  • mental health
  • Acceptance and Commitment Therapy
  • Father
  • child developmental disabilities
  • Virtual reality
  • psychological flexibility
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Inclusion criteria

  • (1) who are the biological fathers of children aged 2 to 12 years
  • (2) with a child having a formal diagnosis of a developmental disability, including autism spectrum disorder, attention deficit/hyperactivity disorder, intellectual disability, or related neurodevelopmental conditions
  • (3) who are able to speak Cantonese and read Chinese

Exclusion criteria

Exclusion Criteria:

  • (1) who are currently undergoing psychotherapies
  • (2) with physical or cognitive impairment and learning problems as identified from NGO or related medical records
  • (3) who exhibit a high risk of serious mental illnesses screened using the Kessler Psychological Distress Scale , with a score of ≥13
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    VR-based ACT

    VR-based ACT for fathers of children with special needs

    Behavioral: VR-based ACT

  • Placebo comparator
    Control

    health talks and simple social support

    Behavioral: Health Talks and Simple Social Support

Interventions

  • BehavioralVR-based ACT

    Participants in the intervention group will be invited to attend 6 weekly sessions of ACT with VR. Each session will last approximately 45-60 minutes.

  • BehavioralHealth Talks and Simple Social Support

    Participants in the control group will receive 6 weekly sessions of health talks and simple social support to mimic the time and attention spent on the intervention group.

05

What researchers measure

Primary outcomes

  1. Screening rate

    Calculated as the number of fathers of children with special needs screened at participated NGOs divided by number of fathers with special needs at participated NGOs during the recruitment period.

    Time frame: During the recruitment period (up to 10 months)

  2. Eligibility rate

    Calculated by dividing the number of fathers who are eligible by the number who are screened.

    Time frame: During the recruitment period (up to 10 months)

  3. Consent rate

    Calculated by dividing the number of fathers who consent to join the study by the number who are eligible.

    Time frame: During the recruitment period (up to 10 months)

  4. Randomization rate

    Calculated by dividing the number of fathers who are randomized into intervention and control groups by those who provide consent.

    Time frame: T1 (start of intervention)

  5. Attendance rate

    Calculated by dividing the number of fathers who complete the intervention by those who are randomized.

    Time frame: T2 (post-intervention at 6 weeks)

  6. Retention rate

    Calculated by dividing the number of fathers who remain in the study by those who are randomized. Retention rates for the intervention and control groups will be calculated at each follow-up.

    Time frame: T2 (post-intervention at 6 weeks), T3 (3 months after intervention), T4 (6 months after intervention)

  7. Adherence rate

    Calculated by dividing the number of fathers who follow the intervention protocol by those who are randomized.

    Time frame: T2 (post-intervention at 6 weeks)

  8. Complete rate

    Calculated by dividing the number of fathers who returned questionnaires by the number of questionnaires distributed. This will be calculated by groups at baseline and each follow-up.

    Time frame: T1 (start of intervention) , T2 (post-intervention at 6 weeks), T3 (3 months after intervention), T4 (6 months after intervention)

  9. Proportion of missing data

    Calculated as the percentage of missing values in the dataset. Unknown or blank values will be considered missing values.

    Time frame: T4 (6 months after intervention)

  10. Adverse events

    Adverse events are defined as unfavorable and unintended events that are not present at baseline, or appear to have worsened during the study.

    Time frame: T4 (6 months after intervention)

Secondary outcomes

  1. Psychological flexibility

    Psychological Flexibility Index (PPFI) will be used to measure psychological flexibility by 19 items rating on a 7-point scale. Higher scores represent greater psychological flexibility. It has been validated among Chinese college students.

    Time frame: T1 (at the start of intervention), T4 (at 6 months after the end of intervention)

  2. Shame

    Shame Scale (version for fathers with children with special needs; SSFCSN) will be used to assess the levels of shame for our participants. It is a 12-item questionnaire (two factors) with good reliability (Cronbach's Alpha = .872) and construct validity across Chinese cultures (Lo, under-reviewed). Responses are recorded on a 6-point scale (1-6), with higher scores indicating greater shame proneness among respondents (fathers) rearing children with special needs.

    Time frame: T1 (at the start of intervention), T4 (at 6 months after the end of intervention)

  3. Guilt

    Guilt Scale (version for fathers with children with special needs; GSFCSN) will be used to record the levels of guilt for our participants. It is an 11-item questionnaire with good reliability and construct validity across Chinese cultures. Responses are recorded on a 6-point scale (1-6), with higher scores indicating higher guilt proneness emotions on respondents (fathers) rearing children with special needs.

    Time frame: T1 (at the start of intervention), T4 (at 6 months after the end of intervention)

  4. Depressive symptoms

    Center for Epidemiologic Studies Depression Scale (CESD) will be used to assess the level of depressive symptoms in participants. It has 20 items on a rating of a 4-point scale. Scores range from 0-60. A score equal to or above 16 indicates a person at risk for clinical depression. This questionnaire has been empirically tested and validated in the Chinese population.

    Time frame: T1 (at the start of intervention), T4 (at 6 months after the end of intervention)

  5. Quality of life (QoL)

    Short Form 6-Dimension (SF-6D) will be used to record the level of QoL in participants. SF-6D contains 6 items that are rated on 4 to 6 response levels. Higher levels indicate a more serious problem. SF-6D is validated in the Hong Kong Chinese population.

    Time frame: T1 (at the start of intervention), T4 (at 6 months after the end of intervention)

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT07459010
Lead sponsor
The Hong Kong Polytechnic University
Responsible party
Dr Katherine Lam (Assistant Professor, The Hong Kong Polytechnic University) — Principal investigator
First posted
Mar 9, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Mar 9, 2026

Study contacts

Ka Wai Katherine LAM, Doctor of Philosophy
Contact
kw-katherine.lam@polyu.edu.hk
+852 27666420

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion